Photo taken from ESMO Open/X
Feb 8, 2024, 17:54
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open’s post on X/Twitter, adding:
“One of the most critical features of novel ADCs is their emerging intracranial activity. Few treatments in oncology allow to achieve >50% intracranial response rates, with durable (PFS 15 months!!) efficacy. Interesting meta-analysis – follow ESMO for more!”
Quoting ESMOs post:
“In a meta-analysis of 10 studies by Michelin et al, published on ESMO Open, T-DXd was found associated with relevant intracranial activity among patients with breast cancer brain metastases (IC-ORR 61%, mPFS 15 months). Read the article here.”
Source: Paolo Tarantino/X and ESMO Open/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08